Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary

BACKGROUND: Cancer of unknown primary (CUP) is heterogeneous and has a wide variety of clinical presentations and a poor prognosis in most patients, with a median overall survival of only 6 months. The development of molecular profiling contributes to precision therapy, and targeted drugs and immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Jie, Wang, Hao, Fan, Honghong, Ding, Junli, Xu, Junying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256999/
https://www.ncbi.nlm.nih.gov/pubmed/35812375
http://dx.doi.org/10.3389/fimmu.2022.900119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256999/
https://www.ncbi.nlm.nih.gov/pubmed/35812375
http://dx.doi.org/10.3389/fimmu.2022.900119

Ejemplares similares